JP6861641B2 - グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法 - Google Patents

グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法 Download PDF

Info

Publication number
JP6861641B2
JP6861641B2 JP2017550154A JP2017550154A JP6861641B2 JP 6861641 B2 JP6861641 B2 JP 6861641B2 JP 2017550154 A JP2017550154 A JP 2017550154A JP 2017550154 A JP2017550154 A JP 2017550154A JP 6861641 B2 JP6861641 B2 JP 6861641B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
human
gcgr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017550154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512417A (ja
JP2018512417A5 (https=
Inventor
ヤン，ハイ
シ，ジム
オー，チョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of JP2018512417A publication Critical patent/JP2018512417A/ja
Publication of JP2018512417A5 publication Critical patent/JP2018512417A5/ja
Application granted granted Critical
Publication of JP6861641B2 publication Critical patent/JP6861641B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017550154A 2015-04-02 2016-03-31 グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法 Expired - Fee Related JP6861641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142257P 2015-04-02 2015-04-02
US62/142,257 2015-04-02
PCT/US2016/025336 WO2016161154A1 (en) 2015-04-02 2016-03-31 Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

Publications (3)

Publication Number Publication Date
JP2018512417A JP2018512417A (ja) 2018-05-17
JP2018512417A5 JP2018512417A5 (https=) 2019-05-09
JP6861641B2 true JP6861641B2 (ja) 2021-04-21

Family

ID=57006366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550154A Expired - Fee Related JP6861641B2 (ja) 2015-04-02 2016-03-31 グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法

Country Status (9)

Country Link
US (2) US10752693B2 (https=)
EP (1) EP3277830A4 (https=)
JP (1) JP6861641B2 (https=)
KR (1) KR20170138456A (https=)
CN (1) CN107614695B (https=)
AU (1) AU2016242935B2 (https=)
CA (1) CA2980765A1 (https=)
MX (1) MX392496B (https=)
WO (1) WO2016161154A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226474B2 (en) 2017-01-09 2019-03-12 Temple University—Of The Commonwealth Sytem Of Higher Education Methods and compositions for treatment of non-alcoholic steatohepatitis
SG11201906682YA (en) * 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
CA3089649A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-tip-1 antibodies and uses thereof
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
CN111068042B (zh) * 2018-10-18 2023-10-13 中山大学 一种多肽化合物在制备治疗非酒精性肝病、特发性肺间质纤维化和动脉硬化药物中的应用
EP3876924A4 (en) * 2018-11-06 2022-08-10 Georgetown University TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS WITH CCK INHIBITORS
KR20210109552A (ko) 2018-12-21 2021-09-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중특이적 단백질
WO2025178928A1 (en) * 2024-02-23 2025-08-28 Remd Biotherapeutics, Inc. Combination therapy for the treatment of obesity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
ES2796556T3 (es) * 2011-09-20 2020-11-27 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de GCGR
MX2015015339A (es) * 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

Also Published As

Publication number Publication date
MX2017012694A (es) 2018-03-07
US10752693B2 (en) 2020-08-25
US20180079820A1 (en) 2018-03-22
CN107614695B (zh) 2022-01-25
EP3277830A1 (en) 2018-02-07
CN107614695A (zh) 2018-01-19
CA2980765A1 (en) 2016-10-06
KR20170138456A (ko) 2017-12-15
MX392496B (es) 2025-03-24
US20200339697A1 (en) 2020-10-29
AU2016242935A1 (en) 2017-11-09
JP2018512417A (ja) 2018-05-17
WO2016161154A1 (en) 2016-10-06
EP3277830A4 (en) 2018-11-21
AU2016242935B2 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP6861641B2 (ja) グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法
US11447555B2 (en) Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
RS65652B1 (sr) Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13
JP2015502975A (ja) ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
IL301252A (en) Use of lepr agonists for pain
JP2019527697A (ja) 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ
US20200353079A1 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
WO2017062693A1 (en) Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
WO2026072993A1 (en) Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210330

R150 Certificate of patent or registration of utility model

Ref document number: 6861641

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees